Asset Details
Do you wish to reserve the book?
Clinical use of whole genome sequencing for Mycobacterium tuberculosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical use of whole genome sequencing for Mycobacterium tuberculosis
Do you wish to request the book?
Clinical use of whole genome sequencing for Mycobacterium tuberculosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical use of whole genome sequencing for Mycobacterium tuberculosis
2016
Overview
Drug-resistant tuberculosis (TB) remains a major challenge to global health and to healthcare in the UK. In 2014, a total of 6,520 cases of TB were recorded in England, of which 1.4 % were multidrug-resistant TB (MDR-TB). Extensively drug-resistant TB (XDR-TB) occurs at a much lower rate, but the impact on the patient and hospital is severe. Current diagnostic methods such as drug susceptibility testing and targeted molecular tests are slow to return or examine only a limited number of target regions, respectively. Faster, more comprehensive diagnostics will enable earlier use of the most appropriate drug regimen, thus improving patient outcomes and reducing overall healthcare costs. Whole genome sequencing (WGS) has been shown to provide a rapid and comprehensive view of the genotype of the organism, and thus enable reliable prediction of the drug susceptibility phenotype within a clinically relevant timeframe. In addition, it provides the highest resolution when investigating transmission events in possible outbreak scenarios. However, robust software and database tools need to be developed for the full potential to be realized in this specialized area of medicine.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V
Subject
/ Antitubercular Agents - pharmacology
/ Antitubercular Agents - therapeutic use
/ Drug resistance in microorganisms
/ Extensively Drug-Resistant Tuberculosis - drug therapy
/ Extensively Drug-Resistant Tuberculosis - epidemiology
/ Extensively Drug-Resistant Tuberculosis - microbiology
/ Genomes
/ Humans
/ Medicine
/ Microbial Sensitivity Tests - methods
/ Mutation
/ Mycobacterium tuberculosis - genetics
/ Mycobacterium tuberculosis - isolation & purification
/ Review
